Phase I Trial of First-Line Bortezomib/Thalidomide plus Chemotherapy for Induction and Stem Cell Mobilization in Patients with Multiple Myeloma
- 1 November 2006
- journal article
- Published by Elsevier in Clinical Lymphoma Myeloma and Leukemia
- Vol. 7 (3) , 210-216
- https://doi.org/10.3816/clm.2006.n.061
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- High-dose chemotherapy with autologous hematopoietic stem cell transplantation in patients with multiple myelomaExpert Review of Anticancer Therapy, 2006
- Development of Effective New Treatments for Multiple MyelomaJournal of Clinical Oncology, 2005
- Bortezomib or High-Dose Dexamethasone for Relapsed Multiple MyelomaNew England Journal of Medicine, 2005
- Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myelomaBritish Journal of Haematology, 2005
- Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapyCancer Cell International, 2005
- Stem cell transplantation in multiple myeloma (0, 1, or 2)Current Opinion in Oncology, 2005
- A phase 2 study of two doses of bortezomib in relapsed or refractory myelomaBritish Journal of Haematology, 2004
- The development of proteasome inhibitors as anticancer drugsPublished by Elsevier ,2004
- A Phase 2 Study of Bortezomib in Relapsed, Refractory MyelomaNew England Journal of Medicine, 2003
- Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341Blood, 2003